1-3 of 3
Jill M. Kolesar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A50: Lapatinib potentiates the antitumor effects of paclitaxel treatment in resistant ovarian cancer cells

Rob McCorkle, Justin W. Gorski, Abigail Anderson, Jill M. Kolesar
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13_Supplement): A50.
https://doi.org/10.1158/1557-3265.OVCA19-A50
Published: 01 July 2020
View article titled, Abstract A50: Lapatinib potentiates the antitumor effects of paclitaxel treatment in resistant ovarian cancer cells
Journal Articles

Abstract B22: Development of the first ovarian carcinosarcoma patient-derived xenograft and tissue organoid model to predict clinical response to chemotherapy

Joseph R. McCorkle, Brian T. Burgess, Anthony B. McDowell, Jodi DeJohn, Christopher P. DeSimone, Frederick R. Ueland, Jill M. Kolesar, Justin W. Gorski
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13_Supplement): B22.
https://doi.org/10.1158/1557-3265.OVCA19-B22
Published: 01 July 2020
View article titled, Abstract B22: Development of the first ovarian carcinosarcoma patient-derived xenograft and tissue organoid model to predict clinical response to chemotherapy
Journal Articles

Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer

Kari B. Wisinski, Amye J. Tevaarwerk, Mark E. Burkard, Murtuza Rampurwala, Jens Eickhoff, Maria C. Bell, Jill M. Kolesar, Christopher Flynn, Glenn Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (11): 2659–2667.
https://doi.org/10.1158/1078-0432.CCR-15-2365
Published: 31 May 2016
View article titled, Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2<sup>+</sup> Breast Cancer
Open the PDF for Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2<sup>+</sup> Breast Cancer in another window